ArticleCancers2025
A Prospective, Multicenter, Randomized, Noninferiority Trial of Stopad
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemostatic products are widely used to control bleeding in hepatic resections. Stopad is a pad-type hemostatic agent containing carboxymethyl chitosan and recombinant thrombin-like hemocoagulase.
methodsWe conducted a prospective, multicenter, randomized, noninferiority study of Stopad vs. Tachosil in 104 patients who required open hepatic resection. The subjects were randomized 1:1 to either the investigational group (Stopad; 53) or the control group (Tachosil; 51).
resultsThe 3-min bleeding control success rate was 92.45% in the Stopad group and 90.20% in the Tachosil group. The lower bound of the one-sided 97.5% confidence level for the between-group difference in the success rate was -9.82%, which was within the preset noninferiority limit of -22.9%. The 5- and 10-min bleeding control success rates were both 100.00% for the Stopad group and were both 98.04% in the Tachosil group. A significantly higher incidence of adverse events was reported in the Stopad group (29/53, 54.72%) than in the Tachosil group (17/51, 33.33%;
conclusionsThe hemostatic efficacy of Stopad was noninferior to that of Tachosil in patients undergoing open hepatic resection, introducing new possibilities for more potent hemostatic products in the future. TRIAL REGISTRATION NUMBER: KCT0004404.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.